Checkpoint Therapeutics Inc. (NASDAQ: CKPT) stock declined by 1.02% at last close whereas the CKPT stock price gains by 7.88% in the pre market session. Checkpoint Therapeutics is basically a company related to immunotherapy and targeted oncology. They focus on the purchase, production, and marketing of new medicines for solid tumour cancer patients.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
CKPT stock’ Recent Update
The company reported that the CONTERNO trial which is a worldwide, randomised Phase 3 trial of cosibelimab in conjunction with pemetrexed and platinum chemotherapy for the first-line care of patients with non-squamous non-small cell lung cancer, has started. Rate of survival (OS) is the main goal for the CONTERNO Phase 3 trial, which is developed to assist full regulatory approvals globally.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
The CONTERNO trial compares cosibelimab (1200 mg every three weeks) with pemetrexed and the platinum chemotherapy selected by investigator (carboplatin or cisplatin) in individuals with previously unmanaged stage IV non-squamous NSCLC and no EGFR mutations or ALK translocations to pemetrexed and platinum chemotherapy alone in patients with previously untreated stage IV non-squamous NSCLC and no EGFR mutations OS is the most important endpoint. Progression-free survival, objective response rate, and safety are all important secondary goals. A total of 560 people will be randomly assigned to receive cosibelimab in combination with chemotherapy or chemotherapy alone in a 2:1 ratio.
While giving his remarks, James F. Oliviero, President and CEO of Checkpoint, said that,they’re looking forward to testing this combination in NSCLC, with the aim of increasing the lifespan of lung cancer patients and removing barriers to possible life-saving immunotherapy medication. Since their inception, the objective has been to approach the biggest markets in this category with an emphasis on extremely competitive pricing, and there is no more important indication to follow through on this strategy than NSCLC, which is expected to grow by 1.7 million additional cases globally by 2020.